Sign In
Buy STTK
$7.92
+0.630 (+8.64%)
At Close: Aug 04, 2026
Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday
06:07pm, Friday, 24'th Jul 2026
He was encouraged by the progress of the company's SL-325. This, the biotech's lead drug candidate, is about to enter Phase 2 clinical testing.
This Shattuck Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday
09:29am, Friday, 24'th Jul 2026
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
Markets took a brutal hit Thursday as oil prices, surging interest rates, and Middle East tensions sent every major index deep into the red. See which stocks analysts are upgrading, downgrading, and i
Shattuck Labs, Inc. (NASDAQ:STTK) Receives $11.00 Average PT from Brokerages
05:49am, Friday, 17'th Jul 2026
Shattuck Labs, Inc. (NASDAQ: STTK - Get Free Report) has received an average recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the stock, MarketBeat reports. One
Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering
12:21am, Wednesday, 10'th Jun 2026
AUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the develo
Shattuck Labs, Inc. Announces Proposed Public Offering
04:18pm, Tuesday, 09'th Jun 2026
AUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the develo
Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update
08:00am, Tuesday, 09'th Jun 2026
AUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-
Shattuck Labs, Inc. (STTK) Discusses Phase I Results for DR3 Blocking Antibody SL-325 and Pipeline Update Transcript
01:18pm, Monday, 08'th Jun 2026
Shattuck Labs, Inc. (STTK) Discusses Phase I Results for DR3 Blocking Antibody SL-325 and Pipeline Update Transcript
Why Is Shattuck Labs Stock Trading Lower On Monday?
12:40pm, Monday, 08'th Jun 2026
Shattuck Labs Inc. (NASDAQ:STTK) stock is down on Monday following news regarding its lead drug candidate, SL-325.
Shattuck Labs Announces Phase 1 Results for SL-325
06:00am, Monday, 08'th Jun 2026
AUSTIN, TX and DURHAM, NC, June 08, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentia
AUSTIN, Texas and DURHAM, N.C., June 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-
Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights
06:15am, Thursday, 07'th May 2026
AUSTIN, Texas and DURHAM, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of pote
Aberdeen Group plc Buys 436,673 Shares of Shattuck Labs, Inc. $STTK
03:08am, Friday, 10'th Apr 2026
Aberdeen Group plc increased its stake in Shattuck Labs, Inc. (NASDAQ: STTK) by 462.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 531,177 shar
Analysts Set Shattuck Labs, Inc. (NASDAQ:STTK) Target Price at $10.50
01:09am, Monday, 06'th Apr 2026
Shattuck Labs, Inc. (NASDAQ: STTK - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are currently covering the firm, Marketbeat.com reports.
Why Shattuck Labs Stock Soared More Than 53% Higher This Week
04:42pm, Friday, 06'th Mar 2026
The biotech published its final earnings report and business covering 2025. It posted a slightly narrower-than-expected net loss for the fourth quarter.
